Table C-12. Baseline demographics in RPS studies

Study	Diagnosis	Age at Diagnosis	Age at Implantation	Eye Implanted (% right)	Time from Implantation to Study Participation	Sex (% male)	Race	Prior Treatments	VA in Study Eye
Arevalo et al. 2015[13,14]	RP	NR	Range: 29–64 years; 1.5 years after implantation	75%	1.3–2.0 years	NR	NR	NR	7 LP, 1 L projection
Ho et al. 2015 and other authors[15-26] Argus II	RP (including 1 with Leber congenital amaurosis) 29 patients, choroideremia 1 patient	NR	Mean: 58 years Range: 28–77 years	NR, but typically worse seeing eye	Implantation is part of the study	70%	NR	NR	Bare LP in both eyes (29 patients), 1 no LP
Seider and Hahn 2015[27]	RP	NR	66 years	0%	Implantation is part of the study	100%	NR	NR	Bare LP
Stingl et al. 2015, 2013[28,29] Alpha IMS	25 RP, 4 rod-cone dystrophy	NR	Mean: 53.8±8.2 years Range: 35–71 years	NR, but worse eye was implanted eye	Implantation is part of the study	55%	NR	NR	LP without projection (20 patients), no LP (9 patients) VA measured by standard flashlight test manually by direct illumination of the eye from 5 directions.
Ayton et al. 2014[30] Bionic Vision	End-stage RP (2 patients rod cone dystrophy, 1 patient Bardet-Biedl syndrome)	NR, but 2 patients had 20 years LP and 1 patient had 8–10 years LP	Mean: 55 years Range: 49–63 years	NR	Implantation is part of this study	66.6%	NR	Guide dog users at the time of study participation	LP: 3 patients

Table C-12. Baseline demographics in RPS studies (continued)

Study	Diagnosis	Age at Diagnosis	Age at Implantation	Eye Implanted (% right)	Time from Implantation to Study Participation	Sex (% male)	Race	Prior Treatments	VA in Study Eye
Rizzo et al. 2014[31] Argus II	RP: 6 patients	NR	Mean: 45.0±10.9 years Range: 36–59 years	66.6%	Implantation is part of the study	83%	NR	5 patients were pseudophakic and 1 was phakic and required a lens extraction	Monocular logMAR acuity that was immeasurable and worse than 2.9
Fujikado et al. 2011[32] STS	Advanced RP	26 years and 55 years	Mean: 69.5 years Range: 67–72 years	0% (left eyes chosen because in both patients, the threshold current to elicit phosphenes by transcorneal electrical stimulation was lower than in the right eye)	Implantation is part of the study	0%	NR	NR	Bare LP: 2 patients How VA measured: NR
Klauke et al. 2011 and other authors[33-37] EPIRET3	RP	NR Duration of legal blindness ranged from 2 to 8 years	Mean: 52.8 years Range: 35–69 years	NR	Implantation is part of this study	33.3%	NR	Artificial lens: 2 patients	LP: 4 patients No LP: 1 patient HM: 1 patient How VA was measured: NR
Zrenner et al. 2011[38] Alpha IMS	RP: 2 patients, choroideremia: 1 patient	Disease onset: 6, 6, and 16 years	Mean: 40.7 years Range: 38–44 years	NR	Implantation is part of the study	66.7%	NR	NR	Blind (bright light stimulation mediated some limited LP without any recognition of shapes) How VA measured: NR

Table C-12. Baseline demographics in RPS studies (continued)

Study	Diagnosis	Age at Diagnosis	Age at Implantation	Eye Implanted (% right)	Time from Implantation to Study Participation	Sex (% male)	Race	Prior Treatments	VA in Study Eye
Chow et al. 2010, Geruschat at al.[3,39] Extension study ASR	RP: autosomal dominant (2 patients), autosomal dominant Usher type 2 (1 patient), Isolated (2 patients), X-linked (1 patient)	NR	Mean: 54 years Range: 41–68 years	100%	Implantation part of study for 4 patients, other 2 patients were enrolled in pilot study for 6 months before taking part in this extension study	83%	83% Cauca-sian	Patient 5 from the pilot trial had cataract removal at time of implantation and an anterior chamber intraocular lens implantation 1-month post ASR implantation. This information was NR for the remaining patients. Use of a long cane (n=4) and guide dog (n=1) were reported by the patients taking part in the orientation and mobility assessment.	CF at 1– 2 feet HM at 4–5 feet HM at 2–3 feet HM at 1–2 feet HM at 5–6 feet HM at 5 feet

Table C-12. Baseline demographics in RPS studies (continued)

Study	Diagnosis	Age at Diagnosis	Age at Implantation	Eye Implanted (% right)	Time from Implantation to Study Participation	Sex (% male)	Race	Prior Treatments	VA in Study Eye
Chow et al. 2004[40] ASR	RP: Isolated without any family history (patient 1), extensive vertical autosomal dominant family history with multiple affected family members (patient 2), autosomal dominant with an affected sibling and child (patient 3), type 2 Usher syndrome with no family history of this condition (patient 4), autosomal dominant RP and a vertical family history (patients 5 and 6 were siblings)	NR	Range: 45–76 years	100%	Implantation was part of study	83%	NR	Posterior chamber intraocular lens (2 patients), anterior chamber intraocular lens (2 patients), uncorrected aphakia (2 patients)	ETDRS letters in either eye at 0.5 m (0 letters OD, 0–3 letters OS) (1 patient), no letters (2 patients), bare to no LP (1 patient), HM at 1 foot (1 patient), CF at 1–2 feet (1 patient)

ASR=Artificial Silicon Retina; CF=counting fingers; ETDRS=Early Treatment of Diabetic Retinopathy Study test; HM=hand motion; logMAR=logarithm of the minimum angle of resolution; L projection=light projection; LP=light perception; NR=not reported; OD=*oculus dexter*, right eye; OS=*oculus sinister*, left eye; RP=retinitis pigmentosa; STS=Suprachoroidal Transretinal Stimulation; VA= visual acuity